Core Insights - Tactile Systems Technology, Inc. has launched its next-generation pneumatic compression platform, Nimbl, for both upper and lower extremity lymphedema treatment, expanding its availability across the U.S. [1][2] Product Features - Nimbl is the smallest pneumatic compression device of its kind, featuring a controller that is 68% lighter and 40% smaller than the previous generation [2] - The lower extremity garment uses 94% less hosing, enhancing transportability and ease of management [2] - Nimbl is the only basic pneumatic compression device with Bluetooth connectivity, allowing patients to track treatments and symptom progress via the Kylee™ digital application [2] Patient-Centric Design - The device is designed to be user-friendly and comfortable, promoting increased adherence to treatment [3] - Its compact design and reduced hose length facilitate easier transport within the home and during travel, improving the overall patient experience [3] Company Overview - Tactile Medical focuses on developing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4] - The company collaborates with clinicians to enhance clinical evidence, raise awareness, and improve patient care while reducing healthcare costs [4]

Company Overview - Tactile Systems Technology, Inc. (Tactile Medical) is a medical technology company focused on providing therapies for individuals with chronic disorders, particularly underserved conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [3]. Leadership Appointment - Laura King has been appointed to the Board of Directors of Tactile Medical and will also serve on the Audit and Compliance & Reimbursement Committees, effective January 13, 2025 [1]. - Ms. King brings over 22 years of experience from General Electric Company (GE), where she held various senior roles, including President & CEO of GE Healthcare's Global Interventional Business [2]. - Her previous leadership roles include co-founding BiaCure, Inc. and Elucent Medical, and serving as President & CEO of NeuWave Medical, which was acquired by Johnson & Johnson's MedTech division [2]. Strategic Impact - The appointment of Laura King is expected to enhance Tactile Medical's capabilities in developing innovative technologies aimed at improving patient care, particularly in the areas of lymphedema and airway clearance therapies [2]. - The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce healthcare costs, and improve the quality of life for patients [3].

Core Viewpoint - Tactile Systems Technology (TCMD) is currently identified as a strong value stock, supported by its favorable valuation metrics and earnings outlook [4][8]. Valuation Metrics - TCMD has a P/E ratio of 21.75, significantly lower than its industry's average P/E of 32.26 [4]. - The stock's P/B ratio stands at 2.10, compared to the industry's average P/B of 4.12, indicating solid valuation [5]. - TCMD's P/S ratio is 1.59, which is lower than the industry's average P/S of 3.03, suggesting it may be undervalued [6]. - The P/CF ratio for TCMD is 20.07, which is also below the industry's average P/CF of 23.27, further supporting the undervaluation thesis [7]. Investment Outlook - The combination of TCMD's strong earnings outlook and its attractive valuation metrics positions it as a compelling investment opportunity for value investors [8].

Company Overview - Tactile Systems Technology (TCMD) shares have increased by 31% over the past month, reaching a new 52-week high of $19.55 [1] - The stock has gained 32.3% year-to-date, outperforming the Zacks Medical sector's 1% and the Zacks Medical - Instruments industry's 5.3% returns [1] Earnings Performance - TCMD has a strong record of positive earnings surprises, not missing earnings consensus estimates in the last four quarters [2] - In the latest earnings report on November 4, 2024, TCMD reported EPS of $0.24, exceeding the consensus estimate of $0.18 [2] Financial Projections - For the current fiscal year, TCMD is expected to post earnings of $0.65 per share on revenues of $292.84 million, reflecting a -48.03% change in EPS and a 6.71% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.86 per share on revenues of $322.36 million, indicating a year-over-year change of 31.44% in EPS and 10.08% in revenues [3] Valuation Metrics - TCMD currently trades at 28.9X current fiscal year EPS estimates, slightly above the peer industry average of 28.8X [7] - On a trailing cash flow basis, the stock trades at 12.3X compared to the peer group's average of 17.3X [7] Zacks Rank and Style Scores - TCMD holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [8] - The stock has a Value Score of A, with Growth and Momentum Scores of C, resulting in a combined VGM Score of B [6][9] Industry Comparison - Fresenius Medical Care AG & Co. KGaA (FMS) is a notable peer with a Zacks Rank of 2 (Buy) and similar style scores [10] - FMS is expected to post earnings of $1.87 per share on revenues of $21.02 billion for the current fiscal year, having beaten consensus estimates by 7.14% last quarter [11] - The Medical - Instruments industry is performing well, ranking in the top 25% of all industries, providing favorable conditions for both TCMD and FMS [12]

MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a fireside chat on Tuesday, December 3rd at 10:00 a.m. Central Time. A ...

Tactile Systems Technology (TCMD) is a Zacks Rank #2 (Buy) that has an A for Value and a C for Growth.  The company develops medical devices for the treatment of chronic diseases at home. Let’s explore more about this company in this Bull of The Day article.DescriptionTactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company wa ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Shares of Tactile Systems Technology (TCMD) have gained 3.1% over the past four weeks to close the last trading session at $14.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.33 indicates a potential upside of 45.9%.The average comprises three short-term price targets ranging from a low of $16 to a high of $25, with a standard deviation of $4.73. While the lowest estimat ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Kyle Bauser - B. Riley Operator Please standby. Welcome, ladies and gentlemen, to the Third Quarter 2024 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only ...

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this medical device maker would post earnings of $0.10 per share when it actually produced earnings of $0.20, delivering a surprise of 100%.Over the last four ...